TY - JOUR

T1 - The role of liquid biopsy in the diagnosis of glioblastoma progression

AU - Ryabova, Anastasiya I.

AU - Novikov, Valery A.

AU - Choynzonov, Evgeny L.

AU - Spirina, Lyudmila V.

AU - Yunusova, Natalia V.

AU - Ponomareva, Anastasiya A.

AU - Tamkovich, Svetlana N.

AU - Gribova, Olga V.

N1 - Publisher Copyright: © 2022, Tomsk National Research Medical Center of the Russian Academy of Sciences. All rights reserved.

PY - 2022

Y1 - 2022

N2 - Purpose: to summarize available data on the diagnostic value of various circulating biomarkers for the detection of glioblastoma recurrence. Material and Methods. A literature search was conducted using PubMED ExoCarta and SILVA databases. Results. Glioblastoma multiforme (GBM) is the most common glioma in adults with an unfavorable prognosis. Treatment of tumor recurrence can improve the survival of patients. Neuroimaging is the standard method of diagnosing brain tumor recurrence. However, a neuroimaging method to clearly distinguish between pseudo progression and tumor progression has not been found to date. Current molecular tumor profiling relies heavily on tissue resection or biopsy. Tissue profiling has several disadvantages in the central nervous system’s tumors, including the challenge associated with invasive biopsy, the heterogeneous nature of many malignancies where a small biopsy can under represent the mutational profile. Liquid biopsy is a promising method in diagnosing malignant tumors. Blood collection is a simple, minimally invasive procedure, but cerebrospinal fluid allows tumor markers to be detected more confidently. However, collection of cerebrospinal fluid is a complex and invasive procedure that can be accompanied by serious complications. Conclusion. Biological fluid markers such as circulating tumor cells, extracellular vesicles, cell-free DNA and cell-free RNA allow for the detection of GMB, determination of molecular genetic features of cancer during response to therapy, and early detection of GBM recurrence.

AB - Purpose: to summarize available data on the diagnostic value of various circulating biomarkers for the detection of glioblastoma recurrence. Material and Methods. A literature search was conducted using PubMED ExoCarta and SILVA databases. Results. Glioblastoma multiforme (GBM) is the most common glioma in adults with an unfavorable prognosis. Treatment of tumor recurrence can improve the survival of patients. Neuroimaging is the standard method of diagnosing brain tumor recurrence. However, a neuroimaging method to clearly distinguish between pseudo progression and tumor progression has not been found to date. Current molecular tumor profiling relies heavily on tissue resection or biopsy. Tissue profiling has several disadvantages in the central nervous system’s tumors, including the challenge associated with invasive biopsy, the heterogeneous nature of many malignancies where a small biopsy can under represent the mutational profile. Liquid biopsy is a promising method in diagnosing malignant tumors. Blood collection is a simple, minimally invasive procedure, but cerebrospinal fluid allows tumor markers to be detected more confidently. However, collection of cerebrospinal fluid is a complex and invasive procedure that can be accompanied by serious complications. Conclusion. Biological fluid markers such as circulating tumor cells, extracellular vesicles, cell-free DNA and cell-free RNA allow for the detection of GMB, determination of molecular genetic features of cancer during response to therapy, and early detection of GBM recurrence.

KW - cell-free DNA

KW - cell-free RNA

KW - circulating tumor cells

KW - extracellular vesicles

KW - glioblastoma recurrence

KW - tumor diagnostics

UR - http://www.scopus.com/inward/record.url?scp=85135752816&partnerID=8YFLogxK

UR - https://www.elibrary.ru/item.asp?id=48756548

UR - https://www.mendeley.com/catalogue/07168c9e-900c-33aa-b665-4fc28c5b306a/

U2 - 10.21294/1814-4861-2022-21-3-104-116

DO - 10.21294/1814-4861-2022-21-3-104-116

M3 - Article

AN - SCOPUS:85135752816

VL - 21

SP - 104

EP - 116

JO - Siberian Journal of Oncology

JF - Siberian Journal of Oncology

SN - 1814-4861

IS - 3

M1 - 11

ER -